droplet digital PCR
Bio-Rad Laboratories Q2 Revenues Decline 6 Percent, Firm Lowers Full-Year Outlook
Bio-Rad is expecting a decline in revenues for the full year due to a slower pace of recovery among customers of its core businesses.
Oncocyte, Bio-Rad Partner to Globally Launch Transplant Test
The test is expected to launch in Q2 2024 to select academic transplant centers in the US and EU and more broadly in the second half of the year.
Bio-Rad, Allegheny Health Network Partner for ddPCR-Based Cancer Monitoring
The collaboration will use Bio-Rad's Droplet Digital PCR technology to gather clinical data for solid tumor MRD monitoring using AHN's patient samples.
The firm expects growth in its ddPCR business this year as it launches new products and the biopharma segment begins to recover from a funding slump.
Cardio Diagnostics Publishes Validation Data for Molecular Coronary Heart Disease Test
The new study in the Journal of the American Heart Association shows that the firm's machine learning-based genetic-epigenetic approach can help diagnose coronary heart disease.